| Objective:Objective:Prostate cancer is more common male malignancy, the serum PSA testing exert important value in the early diagnosis of prostate cancer. In this study, we detected the effects of5a-reductase inhibitors for PSA of early diagnosis marker of prostate cancer, to provide reference information for the effective diagnosis of prostate cancer. At the same time, we analyzed the regulatory mechanism of5a-reductase and PSA in prostate cancer for clarifying the prostate foundation pathological molecular mechanisms.Method:1, Case selection:we chosen80patients with prostate cancer frome Urology of Bao Gang Hospital between years2011-2013,40cases taking5a-reductase inhibitors once was diagnosed as benign prostatic hyperplasia, which further developed prostate cancer,40cases once was diagnosed as benign prostatic hyperplasia and developed prostate cancer or was first discovered with prostate cancer, not taking5a-reductase inhibitors. All cases were divided into two groups, the patients with5a-reductase inhibitors were experimental group, and without5a-reductase inhibitor were the control group. The patients age wsa frome61to85years old, mean age was73.56years old. All patients were not appeared local or distant metastasis at the time of diagnosis.2, The test of serum PSA:Total serum PSA levels (TPSA) and serum levels of free PSA (FPSA) were tested by time-resolved fluorescence immunoassay, and calculated the ratio of TPSA verse FPSA (F/T value).3, Serum PSAD testing:The diameter of the prostate was deteced by5.0MHZB transrectal ultrasound probe, prostate volume V=π/6×X×Y x Z, PSAD=TPSV/V (ng/ml/cm3). Results:1In all prostate cancer patients, the mean serum TPSA was28.199±23.457ng/ml in the experimental group and was40.667±31.107ng/ml in the control group. The serum TPSA values significantly lower in the experimental group compared with the control group, the difference was statistically significant (P <0.05). When the TPSA values wsa less than4ng/ml, the mean of serum TPSA was1.871±0.368ng/ml in experimental group, and was2.198±0.403ng/ml in control group. The TPSA levels was significantly reduced, and the difference statistically was significant (P<0.01). When the TPSA value in range of4-10ng/ml, the mean of serum TPSA was5.970±0.468ng/ml in the experimental group and was8.302±0.660ng/ml in the control group. The TPSA levels was significantly lower compared with the control group, the difference was significant (P<0.01). When TPSA value was greater than lOng/ml, the mean of serum TPSA was48.435±8.057ng/ml in the experimental group, and was66.834±4.956ng/ml in the control group. TPSA value was significantly lower in the experimental group compared with the control group, the difference was significant (P<0.01).2, In all prostate cancer patients, the F/T mean was0.150±0.423in experiment group, and was0.134±0.398in control group. There were no significant difference between the two groups (P>0.05).3, In all prostate cancer patients, the mean of serum PSAD was0.992±0.850ng/ml/cm3in the experimental group and was1.464±1.187ng/ml/cm3in the control group. The PSAD value was significantly lower in the experimental group compared with the control group, the difference was statistically significant (P<0.05). When the TPSA values wsa less than4ng/ml, the mean of PSAD was0.040±0.074ng/ml/cm3in experimental group, and was0.058±0.010ng/ml/cm3in the control group. PSAD was significantly lower in the experimental group compared with the control group, the difference was significant (P<0.01). When the TPSA value in range of4-10ng/ml, the mean of serum PSAD was0.140±0.009ng/ml/cm3in the experimental group, and was0.168±0.011ng/ml/cm3in the control group. PSAD value significantly was lower in the experimental group compared with the control group, the difference was significant (P<0.01). When TPSA value was greater than10ng/ml, the mean of serum PSAD was1.738±0.201ng/ml/cm3in the experimental group, and was2.464±0.177ng/ml/cm3in the control group, PSAD was significantly lower in the experimental group compared with the control group, the difference was significant (P<0.01).Conclusion:1.5a-reductase inhibitors significantly decreased the serum TPSA, PSAD in patients of prostate cancer, and in less than4ng/ml,4-10ng/ml, greater than10ng/ml. It provide provide effective reference letter for PSA diagnostic use for prostate cancer once using5a-reductase inhibitors.2、5a-reductase and PSA may play an important role in the development mechanisms of prostate cancer.3、5a-reductase inhibitors may take preventive effect on prostate cancer and also have a therapeutic effect when wsa used to treat benign prostatic hyperplasia, which need further study. |
PDF Full Text Request